●Selective Action: Binds exclusively to ghrelin receptors in the pituitary, avoiding activation of adrenal or prolactin pathways.
●Extended Half-Life: Approximately 2 hours, allowing for sustained GH pulses without frequent dosing.
●Non-Hunger Inducing: Unlike GHRP-6, it doesn't stimulate appetite, making it ideal for cutting phases.
●Stability: Resistant to enzymatic degradation, enhancing bioavailability via subcutaneous injection.
●Safety Profile: Low incidence of side effects, validated in clinical trials for postoperative ileus, indicating its therapeutic potential.






